Neuroinflammation as a potential therapeutic target in dementia with Lewy bodies

The more reliably identifiable prodromal phase of dementia with Lewy bodies than Alzheimer's disease provides a critical opportunity for intervention

There is a great deal of evidence suggesting a fundamental role of central and peripheral inflammation in the pathogenesis of Alzheimer's disease (AD).1 Neuropathological and neuroradiological studies have indicated that activated microglia and inflammation-related mediators is observed in the cerebral neocortex of patients with early AD before extensive tau-related neurofibrillary pathology develops. Numerous epidemiological studies have revealed that treatment with non-steroidal anti-inflammatory drugs decreases the risk for developing AD. However, several prospective clinical trials showed no benefit from anti-inflammatory drugs in patients with symptomatic AD. These results imply that therapies should be initiated during earlier stages of AD pathology. Although it has been established that AD can be identified during early stages using cerebrospinal fluid profiles and amyloid positron emission tomography imaging, these biomarkers are not...

from #ORL-AlexandrosSfakianakis via ola Kala on Inoreader http://ift.tt/2FL5AQG